直接口服抗凝药与维生素K拮抗剂出血部位差异:基于VigiBase的药物警戒研究
基于WHO VigiBase数据库2008至2021年成人出血报告,比较DOAC与VKA的出血部位差异。Xa抑制剂较达比加群出血报告风险更高(除消化道出血外)。
要点
- DOAC较VKA脑血管、泌尿及鼻出血报告更少,妇科出血更多。
- DOAC与VKA在消化道和皮肤出血部位无显著差异。
- Xa抑制剂较达比加群各部位出血报告风险更高(除消化道出血)。
核心结论
- 真实世界中DOAC与VKA的出血部位差异不限于脑或消化道,Xa抑制剂与凝血酶抑制剂间也存在显著差异。
研究设计与样本
- 主要比较DOAC与VKA的出血部位,次要比较Xa抑制剂与凝血酶抑制剂的出血部位。
- 结果以调整年龄、性别、报告来源及合并用药后的报告比值比(ROR)及其95%CI表示。
主要发现
- DOAC组平均事件发生时间7.6个月,VKA组29.9个月(P < .001)。
- DOAC较VKA脑血管、泌尿及鼻出血报告显著减少,妇科出血报告显著增加。
- DOAC与VKA在消化道和皮肤出血部位无显著差异。
- Xa抑制剂较达比加群各部位出血报告风险更高(除消化道出血外)。
临床怎么用
- 临床选择抗凝药时应关注不同药物出血部位谱的差异,而不仅限于脑或消化道出血。
- 对使用DOAC的女性患者需关注妇科出血风险。
- Xa抑制剂与达比加群的非消化道出血报告风险存在差异,处方时需结合患者个体情况权衡。
局限性
- 研究基于自发报告数据库,存在报告偏倚和混杂因素,不能直接推断因果关系。
- 仅纳入成人报告,未涵盖儿童等特殊人群。
- 未报告各出血部位的具体ROR数值及95%CI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Clinical trials have found differences in bleeding locations between direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA). The present study was performed to investigate these differences in real life using reports of adverse drug reactions registered in the World Health Organization's pharmacovigilance database, VigiBase®. METHODS: All bleeding registered between 1 January 2008 and 31 December 2021 in adults were included. The main objective was to compare bleeding locations reported with DOAC with those with VKA. As a secondary objective, we performed the same comparison with Xa vs. thrombin inhibitors. Results were presented as reporting odds ratios (RORs) adjusted on age, gender, origin of reports and co-medications with their 95% confidence interval. RESULTS: During this 14-year period, 142 228 instances of bleeding were registered with oral anticoagulants, including 39 570 with VKA and 102 658 with DOAC. Mean time to event was lower with DOAC (7.6 months) than with VKA (29.9 months) (P < .001). Significant differences in bleeding locations were found in the reports with less cerebral, urologic and nasal bleeding, more gynaecologic bleeding with DOAC than with VKA, without any significant differences in digestive and cutaneous locations. A higher risk of bleeding reports was found with Xa inhibitors vs. dabigatran whatever the locations (except digestive bleeding). CONCLUSION: This real-life study shows that the differences in bleeding locations between DOAC and VKA are not limited to the brain or gastrointestinal tracts. Significant differences were also found between Xa and thrombin inhibitors.
引用
- Montastruc JL, Tessier S, Bura-Riviere A, et al. Differences in the location of bleeding with direct oral anticoagulants vs. vitamin K antagonists: A study in the World Health Organization's pharmacovigilance database. Br J Clin Pharmacol. 2023. PMID: 36799080. doi:10.1111/bcp.15693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。